Coronavirus vaccine expectations might be getting unrealistic


Some experts think there's been a communication problem when it comes to potential coronavirus vaccines, which has led to unrealistic expectations among the general population, Stat News reports.
That doesn't mean they aren't hopeful, or even optimistic, that one of the many vaccines in development will prove effective. The confusion is more about how widely available doses will be, if and when one is in production. "I don't think we're communicating very well at all with the public, because I keep having to tell these people, you know, even if we had a vaccine that showed some evidence of protection by September, we are so far from having a vaccine in people's arms," said Michael Osterholm, the director of the University of Minnesota's Center for Infectious Diseases Research and Policy.
If something is ready by September, like the vaccines being tested by Pfizer or the University of Oxford, they would likely only be available for emergency use, and health care workers would seemingly get the first batch of doses, Stat reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
Production capacity will be a major holdup — companies are working rapidly to find a vaccine, and will continue to do so when making doses (which many argue should begin even before a potential vaccine is proven to work), but the sheer number of people who will require a vaccine, there's a long way to go; demand will far outweigh supply for a while. "I don't think that the general population will have a vaccine probably until the second half of 2021," said Robin Robinson, who formerly led the Biomedical Advanced Research and Development Authority. "And that's if everything goes OK." Read more at Stat News.
A free daily email with the biggest news stories of the day – and the best features from TheWeek.com
Tim is a staff writer at The Week and has contributed to Bedford and Bowery and The New York Transatlantic. He is a graduate of Occidental College and NYU's journalism school. Tim enjoys writing about baseball, Europe, and extinct megafauna. He lives in New York City.
-
Lemon and courgette carbonara recipe
The Week Recommends Zingy and fresh, this pasta is a summer treat
-
Corbynism returns: a new party on the Left
Talking Point Jeremy Corbyn and Zarah Sultana's breakaway progressive party has already got off to a shaky start
-
Oasis reunited: definitely maybe a triumph
Talking Point The reunion of a band with 'the power of Led Zeppelin' and 'the swagger of the Rolling Stones'
-
Measles cases surge to 33-year high
Speed Read The infection was declared eliminated from the US in 2000 but has seen a resurgence amid vaccine hesitancy
-
Kennedy's vaccine panel signals skepticism, change
Speed Read RFK Jr.'s new vaccine advisory board intends to make changes to the decades-old US immunization system
-
Kennedy ousts entire CDC vaccine advisory panel
speed read Health Secretary RFK Jr. is a longtime anti-vaccine activist who has criticized the panel of experts
-
RFK Jr. scraps Covid shots for pregnant women, kids
Speed Read The Health Secretary announced a policy change without informing CDC officials
-
New FDA chiefs limit Covid-19 shots to elderly, sick
speed read The FDA set stricter approval standards for booster shots
-
US overdose deaths plunged 27% last year
speed read Drug overdose still 'remains the leading cause of death for Americans aged 18-44,' said the CDC
-
Trump seeks to cut drug prices via executive order
speed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr. visits Texas as 2nd child dies from measles
Speed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths